About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
N
Approaches to Preventing and Treating GVHD in 2024
By
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
FEATURING
Nasheed Hossain
By
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
FEATURING
Nasheed Hossain
26 views
March 11, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
05:47
Meletios Dimopoulos
PERSEUS Study Primary Results: Daratumumab + VRd vs. VRd Alone in Pa…
35:37
University of Colorado Division of Hematology
2024 Updates on Multiple Myeloma Treatment
Feat.
D. Sherbenou
06:23
Integrity Continuing Education
ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VR…
Feat.
O. Landgren
05:56
ASH 2022 Conference Coverage
ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalido…
Feat.
G. Morgan
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course
Overview of Hematopoietic Cell Transplantation
Feat.
R. Salit
13:05
Moffitt Cancer Center
Newly Diagnosed Myeloma: Why We Should Use a Response-Adapted Approa…
Feat.
K. Shain
18:27
Indy Hematology Review
DEBATE: Why Not to Transplant When MRD Has Been Achieved After Initi…
Feat.
J. Mikhael
52:39
Yale Cancer Center
Myeloma in 2023: So Many Drugs, Yet So Few Cures
Feat.
A. Chari
41:54
University of Colorado Division of Hematology
Overview of Pathophysiology, Diagnosis and Management of Multiple My…
Feat.
K. Sidor
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Chronic GVHD: A Case-Based Discussion
Feat.
L. Perry
21:11
MyCancerHaven
Experts Discuss the Future of Stem Cell Transplantation in Myeloma
Feat.
R. Vij,
N. Callander
13:55
Moffitt Cancer Center
Newly Diagnosed Myeloma: Why We Should NOT Use a Response-Adapted Ap…
Feat.
O. Castañeda-Puglianini
15:49
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 DEBATE: Early HDM-aSCT in MM Is No Longer the SoC
Feat.
C. Mo
15:53
Indy Hematology Review
DEBATE: Transplanting the MRD- Myeloma Patients for a Deeper Remissi…
Feat.
S. Usmani
15:53
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Managing Newly Diagnosed Myeloma in 2024
Feat.
A. Garfall
11:56
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 DEBATE: Upfront HCT for Newly Diagnosed Multiple Myeloma
Feat.
N. Callander
27:47
City of Hope
Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…
Feat.
I. Amanam
11:02
Winship Cancer Institute - Emory University
Multiple Myeloma: Clinical Challenges for the Community Clinician
Feat.
N. Joseph
08:02
ASH 2022 Conference Coverage
ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…
Feat.
S. Holtan